Literature DB >> 24099668

Epigenetic silencing of CXCL14 induced colorectal cancer migration and invasion.

Baoping Cao1, Yunsheng Yang, Yuanming Pan, Yan Jia, Malcolm V Brock, James G Herman, Mingzhou Guo.   

Abstract

To explore epigenetic regulation and the impact of chemokine CXCL14 on colorectal cancer, 7 colorectal cancer cell lines, 107 cases of primary colorectal cancer, and 10 cases of normal colorectal mucosa were evaluated in this study. Methylation specific PCR (MSP), semi-quantitative reverse-transcription PCR (RT-PCR), cell proliferation assay, colony formation, and transwell assay were performed for the evaluation. Complete methylation and loss of CXCL14 expression were found in 5 colorectal cancer cell lines. Partial methylation and weak expression were found in two cell lines. CXCL14 was methylated in 79.4% (85/107) of primary human colorectal cancer. No methylation was found in 10 cases of normal colorectal mucosa. Restoration of CXCL14 expression was induced by the 5-aza-2'-deoxycytidine (DAC) treatment. The cell viability was reduced and colony formation was inhibited by restoration of CXCL14 expression in HCT116 cells, a colorectal cancer cell line. The number of invasive and migration cells was reduced by CXCL14. The expression of MMP-2, Vimentin, and NF-κB was suppressed, and the expression of E-cadherin and IκB-α was induced by CXCL14. In conclusion, CXCL14 is frequently methylated in human colorectal cancer and promoter region hypermethylation silenced CXCL14 expression in colorectal cancer cells. Restoration of CXCL14 expression suppressed colorectal cancer proliferation. CXCL14 inhibits colorectal cancer migration, invasion, and epithelial-to-mesenchymal transition (EMT) by suppressing NF-κB signaling.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24099668      PMCID: PMC4061567     

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  30 in total

Review 1.  Chemokines, chemokine receptors and the gastrointestinal system.

Authors:  Hiroshi Miyazaki; Kazuaki Takabe; W Andrew Yeudall
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.742

2.  CXCL14 enhances proliferation and migration of NCI-H460 human lung cancer cells overexpressing the glycoproteins containing heparan sulfate or sialic acid.

Authors:  Cho Rong Park; Dong-Joo You; Dong-Kyu Kim; Mi Jin Moon; Cheolju Lee; Seung-Hyun Oh; Curie Ahn; Jae Young Seong; Jong-Ik Hwang
Journal:  J Cell Biochem       Date:  2013-05       Impact factor: 4.429

3.  Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo.

Authors:  Galina V Shurin; Robert L Ferris; Robert Ferris; Irina L Tourkova; Lori Perez; Anna Lokshin; Levent Balkir; Bobby Collins; Gurkamal S Chatta; Michael R Shurin
Journal:  J Immunol       Date:  2005-05-01       Impact factor: 5.422

4.  Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells.

Authors:  Eun Young Song; Michael R Shurin; Irina L Tourkova; Dmitriy W Gutkin; Galina V Shurin
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

5.  Methylation-induced silencing of ASC/TMS1, a pro-apoptotic gene, is a late-stage event in colorectal cancer.

Authors:  Marco A Riojas; Mingzhou Guo; Sabine C Glöckner; Emi Ota Machida; Stephen B Baylin; Nita Ahuja
Journal:  Cancer Biol Ther       Date:  2007-08-03       Impact factor: 4.742

6.  SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer.

Authors:  Dongtao Yin; Yan Jia; Yuanzi Yu; Malcolm V Brock; James G Herman; Chao Han; Xiaomo Su; Yang Liu; Mingzhou Guo
Journal:  Discov Med       Date:  2012-07       Impact factor: 2.970

7.  Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer.

Authors:  Luciane R Cavalli; Rebecca B Riggins; Antai Wang; Robert Clarke; Bassem R Haddad
Journal:  Breast Cancer Res Treat       Date:  2009-08-21       Impact factor: 4.872

8.  Promoter methylation of HIN-1 in the progression to esophageal squamous cancer.

Authors:  Mingzhou Guo; Jingli Ren; Malcolm V Brock; James G Herman; Hetty E Carraway
Journal:  Epigenetics       Date:  2008-11-08       Impact factor: 4.528

9.  Expression of CXCL14 and its anticancer role in breast cancer.

Authors:  Xiao-Li Gu; Zhou-Luo Ou; Feng-Juan Lin; Xiao-Li Yang; Jian-Min Luo; Zhen-Zhou Shen; Zhi-Ming Shao
Journal:  Breast Cancer Res Treat       Date:  2012-08-22       Impact factor: 4.872

10.  BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells.

Authors:  Thomas D Shellenberger; Mary Wang; Manu Gujrati; Arumugam Jayakumar; Robert M Strieter; Marie D Burdick; Constantin G Ioannides; Clayton L Efferson; Adel K El-Naggar; Dianna Roberts; Gary L Clayman; Mitchell J Frederick
Journal:  Cancer Res       Date:  2004-11-15       Impact factor: 12.701

View more
  24 in total

1.  Epigenetic silencing BCL6B induced colorectal cancer proliferation and metastasis by inhibiting P53 signaling.

Authors:  Sui Hu; Baoping Cao; Meiying Zhang; Enqiang Linghu; Qimin Zhan; Malcolm V Brock; James G Herman; Gaoping Mao; Mingzhou Guo
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

2.  EBP50 inhibits the migration and invasion of human breast cancer cells via LIMK/cofilin and the PI3K/Akt/mTOR/MMP signaling pathway.

Authors:  Hongli Li; Baogang Zhang; Yuqing Liu; Chonggao Yin
Journal:  Med Oncol       Date:  2014-08-14       Impact factor: 3.064

Review 3.  Evolving notions on immune response in colorectal cancer and their implications for biomarker development.

Authors:  Fabio Grizzi; Gianluca Basso; Elena Monica Borroni; Tommaso Cavalleri; Paolo Bianchi; Sanja Stifter; Maurizio Chiriva-Internati; Alberto Malesci; Luigi Laghi
Journal:  Inflamm Res       Date:  2018-01-10       Impact factor: 4.575

Review 4.  Advances in Research on the Effects and Mechanisms of Chemokines and Their Receptors in Cancer.

Authors:  Jing Xu; Jing-Quan Li; Qi-Lei Chen; Elena A Shestakova; Vsevolod A Misyurin; Vadim S Pokrovsky; Elena M Tchevkina; Hu-Biao Chen; Hang Song; Jian-Ye Zhang
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

Review 5.  The multifarious roles of the chemokine CXCL14 in cancer progression and immune responses.

Authors:  Joseph A Westrich; Daniel W Vermeer; Paul L Colbert; William C Spanos; Dohun Pyeon
Journal:  Mol Carcinog       Date:  2020-03-24       Impact factor: 4.784

6.  Methylation of NRN1 is a novel synthetic lethal marker of PI3K-Akt-mTOR and ATR inhibitors in esophageal cancer.

Authors:  Wushuang Du; Aiai Gao; James G Herman; Lidong Wang; Lirong Zhang; Shunchang Jiao; Mingzhou Guo
Journal:  Cancer Sci       Date:  2021-05-16       Impact factor: 6.716

Review 7.  Epigenetic regulation of inflammatory cytokines and associated genes in human malignancies.

Authors:  Rehana Yasmin; Sami Siraj; Amjad Hassan; Abdul Rehman Khan; Rashda Abbasi; Nafees Ahmad
Journal:  Mediators Inflamm       Date:  2015-03-01       Impact factor: 4.711

8.  Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.

Authors:  Xin Li; Jie Yu; Malcolm V Brock; Qian Tao; James G Herman; Ping Liang; Mingzhou Guo
Journal:  Oncotarget       Date:  2015-05-10

Review 9.  Role of Chemokines in Non-Small Cell Lung Cancer: Angiogenesis and Inflammation.

Authors:  Selma Rivas-Fuentes; Alfonso Salgado-Aguayo; Silvana Pertuz Belloso; Patricia Gorocica Rosete; Noé Alvarado-Vásquez; Guillermo Aquino-Jarquin
Journal:  J Cancer       Date:  2015-08-07       Impact factor: 4.207

10.  Suppressed rate of carcinogenesis and decreases in tumour volume and lung metastasis in CXCL14/BRAK transgenic mice.

Authors:  Ryu-Ichiro Hata; Kazuhito Izukuri; Yasumasa Kato; Soichiro Sasaki; Naofumi Mukaida; Yojiro Maehata; Chihiro Miyamoto; Tetsu Akasaka; Xiaoyan Yang; Yoji Nagashima; Kazuyoshi Takeda; Tohru Kiyono; Masaru Taniguchi
Journal:  Sci Rep       Date:  2015-03-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.